title: [An analysis of prognostic factors in patients with prostatic cancer after hormone therapy and radiotherapy].
abstract: To investigate prognostic factors for prostatic cancer, 110 patients who had received hormonal treatment (HT) and 43 patients who had received radiotherapy (RT) were studied. Age of the patients ranged from 49 to 92 years old (median 71 years old) and follow-up period ranged from 3 to 164 months (median 50 months). Survival rate was calculated by Kaplan-Meier method with statistical analysis based upon Cox's proportional hazards regression model. This analysis identified performance status as the most important factor for al patients, followed by histological grade for patients HAVING received HT, and lymph node metastasis for patients received having RT. The result suggests that routine clinical data provide a good indicator as to the prognosis of prostatic cancer.
authors.affiliation: Department of Urology, Hiroshima University School of Medicine, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Tacho
authors.forename: M
authors.initials: M
authors.lastname: Ikawa
authors.forename: A
authors.initials: A
authors.lastname: Matsubara
authors.forename: T
authors.initials: T
authors.lastname: Shirane
authors.forename: M
authors.initials: M
authors.lastname: Fukushima
authors.forename: M
authors.initials: M
authors.lastname: Nakahara
authors.forename: K
authors.initials: K
authors.lastname: Sagami
authors.forename: T
authors.initials: T
authors.lastname: Usui
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D003131:Combined Modality Therapy; D045166:Estradiol Congeners / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016016:Proportional Hazards Models; D011471:Prostatic Neoplasms / Q000401:mortality / Q000532:radiotherapy / Q000628:therapy*; D011879:Radiotherapy Dosage; D015996:Survival Rate
chemical_list: D045166:Estradiol Congeners